Ixempra - 2007 FDA approvals

Drug: Ixempra (ixabepilone)
Indication: Cancer
Company: Bristol-Myers Squibb
Approval Date: October 16, 2007

Scoop: Ixempra gained FDA approval as a stand-alone treatment for patients who've failed other chemotherapy and for use with Roche's Xeloda in patients whose cancer has spread. Ixempra is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones. A treatment course of Ixempra is expected to cost $18,000 to $23,000, and is expected to earn BMS $500 million in annual sales by 2010.

More News:
BMS cancer med could earn $500M. Report

Ixempra - 2007 FDA approvals
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.